Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review.

Page MJ, Moher D. · 2017

Read Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review. by Page MJ, Moher D. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5738221.txt.

Introduction

Page and Moher map research on the PRISMA statement, a guide for reporting systematic reviews. Seven extensions of the guide have appeared, with eight more in the works. Their scoping review asks how far the guide is used. It also asks how well reviews follow its items.

They found 100 studies on uptake and impact. Most data cover how well reviews stick to the main statement. Pooled results show many items are still reported poorly. Even reviews after 2009 often miss key items. The authors suggest an updated statement plus tools to help journals enforce it.

Catalog record

CREATORPage MJ, Moher D.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5738221

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review By Matthew J Page, David Moher Published in: Systematic Reviews DOI: 10.1186/s13643-017-0663-8 ABSTRACT Abstract Background The PRISMA Statement is a reporting guideline designed to improve transparency of systematic reviews (SRs) and meta-analyses. Seven extensions to the PRISMA Statement have been published to address the reporting of different types or aspects of SRs, and another eight are in development. We performed a scoping review to map the research that has been conducted to evaluate the uptake and impact of the PRISMA Statement and extensions. We also synthesised studies evaluating how well SRs published after the PRISMA Statement was disseminated adhere to its recommendations. Methods We searched for meta-research studies indexed in MEDLINE® from inception to 31 July 2017, which investigated some component of the PRISMA Statement or extensions (e.g. SR adherence to PRISMA, journal endorsement of PRISMA). One author screened all records and classified the types of evidence available in the studies. We pooled data on SR adherence to individual PRISMA items across all SRs in the included studies and across SRs published after 2009 (the year PRISMA was disseminated). Results We included 100 meta-research studies. The most common type of evidence available was data on SR adherence to the PRISMA Statement, which has been evaluated in 57 studies that have assessed 6487 SRs. The pooled results of these studies suggest that reporting of many items in the PRISMA Statement is suboptimal, even in the 2382 SRs published after 2009 (where nine items were adhered to by fewer than 67% of SRs). Few meta-research studies have evaluated the adherence of SRs to the PRISMA extensions or strategies to increase adherence to the PRISMA Statement and extensions. Conclusions Many studies have evaluated how well SRs adhere to the PRISMA Statement, and the pooled result of these suggest that reporting of many items is suboptimal. An update of the PRISMA Statement, along with a toolkit of strategies to help journals endorse and implement the updated guideline, may improve the transparency of SRs. Electronic supplementary material The online version of this article (10.1186/s13643-017-0663-8) contains supplementary material, which is available to authorized users. Keywords: Reporting, Systematic reviews, Methodology, Quality BACKGROUND Systematic reviews (SRs) and meta-analyses are an essential resource for healthcare decision-makers [1]. When conducted well, SRs can provide credible and timely data on a range of enquiries, such as which treatments are effective, ineffective or harmful; which tests accurately diagnose a condition and which exposures are associated with health outcomes. However, the value of SRs depends on how well authors have reported what they did, and what they found. If such information is absent or ambiguous, readers cannot judge whether the results of the SR are robust to the methods used, cannot attempt to reproduce the findings and cannot interpret the findings accurately. This can contribute to the failure to implement the findings of SRs into clinical practice [2]. Therefore, transparent reporting of SRs should be considered critically important by authors of SRs [3, 4]. The transparency of SRs and meta-analyses of health research has been called into question on many occasions [5]. The first formal appraisal of SRs with a focus on medicine was performed by Cynthia Mulrow, who identified several poor reporting practices in a sample of 50 medical review articles published between June 1985 and June 1986 [6]. For example, clearly specified methods of identifying, selecting and appraising studies were available in one article only. Transparency was only slightly better in reviews published in 1996, with less than 25% of articles describing how evidence was identified, evaluated or synthesised [7]. In the last decade, transparency of SRs has certainly improved, yet a high amount of suboptimal reporting persists [8]. Improvements in the transparency of SRs in recent years may be attributed to the dissemination of reporting guidelines. Reporting guidelines provide evidence-based recommendations for authors on how to report their research methods and findings clearly [9]. In 1999, an international group of 30 epidemiologists, clinicians, statisticians, editors and researchers developed a reporting guideline for meta-analyses of randomised trials—the QUOROM (QUality Of Reporting Of Meta-analyses) Statement [10]. In 2005, a meeting was convened to update QUOROM to address several conceptual and practical advances in the methodology of SRs and to help overcome several shortcomings identified in an audit of SRs [3]. The guideline was renamed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) Statement, and published in 2009 [11]. It was accompanied by an explanation and elaboration document, which provided detailed guidance for each of the 27 included items, and examples of exemplar reporting [12]. According to citation data in Scopus®, the PRISMA Statement has had a very high uptake from the biomedical research community (Fig. 1). The checklist paper [11, 13–19] has been cited 19,402 times as of 31 July 2017, and the accompanying explanation and elaboration document [12, 20–23] received 5483 citations by this date. However, not all published SRs cite the guideline; for example, in a random sample of 119 non-Cochrane SRs of therapeutic interventions indexed in MEDLINE® in February 2014, 42 (35%) mentioned the use of the PRISMA Statement [8]. [Figure: Cumulative number of citations of the PRISMA Statement. Data obtained from Scopus® on 31 July 2017. E&E explanation and elaboration] Since its publication, seven extensions to the PRISMA Statement have been developed to facilitate reporting of different types or aspects of SRs (Table 1). These include the PRISMA-Equity extension [24–26], PRISMA for Abstracts of SRs [27], PRISMA extension for reporting SRs incorporating network meta-analysis [28], PRISMA for SRs and meta-analyses of individual participant data [29], PRISMA for SR protocols [30, 31], PRISMA harms checklist [32] and PRISMA extension for SRs of complex interventions [33, 34]. Citation counts for the PRISMA extensions are much lower than those of the PRISMA Statement, but they have not had the same amount of time to accrue citations (Fig. 2). Also, one should not expect the extensions to receive as many citations, as they are more restricted in scope, meaning that fewer SRs to which the extensions are applicable are published each year. The most cited extension is the checklist paper for PRISMA-P (for SR protocols) [30], which has received 683 citations since its publication in January 2015. [Table: Scope of the PRISMA Statement and published extensions] [Figure: Cumulative number of citations of PRISMA extensions published before 2017. Data obtained from Scopus® on 31 July 2017. E&E explanation and elaboration, IPD individual participant data, NMA network meta-analysis] There are also eight PRISMA extensions that are in development (Table 2). These include extensions for SRs of newborn and child health research and for protocols of such SRs, for SRs of diagnostic test accuracy studies, for rapid reviews, for scoping reviews, for SR search methods, for SRs of traditional Chinese medicine interventions and for SRs of in vivo animal studies. [Table: Scope of the PRISMA extensions in development] It is important to evaluate whether the PRISMA Statement and extensions have achieved what they are designed to do—improve the transparency of SRs. We are aware of two previous SRs that have investigated the adherence of SRs to the PRISMA Statement (i.e.

Read the complete text